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ABSTRACT 
A case of human immunodeficiency virus (HIV) infection fol- 
lowing heart transplantation is reported. The patient acquired 
HIV infection at surgery after receiving blood transfusions from 
an HIV seronegative donor who subsequently seroconvet-ted. 
The patient was followed for 84 months following transplanta- 
tion. He was immunosuppressed with cyclosporine and pred- 
nisone and his CD4+ lymphocyte count remained less than 
200 cells/mm3. Before death, a progressive worsening of car- 
diac function was observed without any evidence of acute or 
chronic rejection. Death due to end-stage cardiomyopathy in 
the presence of opportunistic infections occurred suddenly. 
Cardiomyopathy might have been related to either antiretro- 
viral treatment or HIV infection or both. The patient had a long- 
term survival, in spite of chronic immunosuppression, early 
development of low CD4+ count and early onset of an acquired 
immunodeficiency syndrome (AIDS)-defining illness. The pos- 
sibility of a synergistic antiretroviral activity of cyclosporine in 
combination with zidovudine is discussed. Reported cases of 
HIV infection acquired after heart transplantation are reviewed. 
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Human immunodeficiency virus (HIV) infection follow- 
ing heart transplantation rarely has been reported to 
date,lF5 and little is known about the course of HIV infec- 
tion in patients who have undergone heart transplanta- 
tion.This report presents a case of HIV infection acquired 
after heart transplantation, with development of cardio- 
myopathy after long-term survival. 
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CASE REPORT 
A 45year-old man, without risk factors for HIV infection, 
underwent heart transplantation in January 1987 because 
of end-stage cardiopathy following aortic valve replace- 
ment. The patient was negative for HIV antibodies at 
transplantation. During surgery, the patient received sev- 
eral units of packed red blood cells and platelets.Two 
months later the patient seroconverted to HIV antibody 
positivity. Seroconversion was asymptomatic. Since one of 
the blood donors seroconverted in the meantime, the 
source of infection was identified.The clinical course of 
HIV infection during the following years is summarized 
inTable 1. 
The patient was administered immunosuppressive 
therapy with cyclosporine, prednisone, and azathioprine. 
At diagnosis CD4+ lymphocyte count was 168/mm3. Dur- 
ing follow-up, the patient presented with monoder- 
matomeric thoracic herpes roster in June 1988, acute 
pancreatitis in October 1988, and mild Pneumocystis 
carinii pneumonia (FCP) in November 1989. 
Zidovudine (AZT) treatment was started in January 
1990 and was continued for the following 4 years. In July 
1990, secondary PCP prophylaxis was begun with 
aerosolized pentamidine. The course of HIV infection, 
apparently severe when considering the persistently low 
CD4+ count, slowly progressed despite persistently 
detectable viral antigenemia.The patient remained asymp- 
tomatic during antiretroviral treatment. Zidovudine was 
discontinued after the episode of PCP 
At echocardiographic follow-up late in 1992, dilata- 
tion of the right ventricle and a mild reduction in left 
ventricular compliance, with mild reduction in antero- 
apical kinesis, were observed. 
In January 1994, the patient was admitted to the 
Division of Infectious Diseases with dyspnea. He had no 
fever.A chest x-ray showed interstitial infiltrates at the 
lower right lobe, bilateral pleural effusions and an 
enlarged heart; an echocardiographic examination 
yielded a hypokinetic heart, with an ejection fraction of 
approximately 30%; bronchoalveolar lavage fluid was 
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Table 1. Clinical Course 
Lowest Serum HIV Immuno- Other 
CDC CD4+ CD4/ ~24 Ag* suppressive Rejection Antiretroviral HIV-Related 
Year Stage HIV-Related Diseases Count/mm3 CD8 WW Treatment Episodes Treatment Treatment 
1987 I-11 No 
1988 III Monodermatomeric 
herpes zoster / acute 
pancreatitis 
1989 IVCl PCP / hairy leukoplakia 
1990 IVCI No 162 0.18 113 
1991 IVCI No 
1992 IVCI No 
1993 IVCI No 
1994 IV Cl PCP / CMV pneumonia 
168 
43 
97 
149 
182 
104 
184 
0.56 
0.27 
0.29 
0.29 
0.20 
0.23 
0.13 
41 
26 
103 
197 
ND 
52 
61 
Cyclosporine 
240 mg 
Prednisone 
10mg 
Cyclosporine 
240 mg 
Prednisone 
10mg 
Azathioprine 
125 mg 
Cyclosporine 
280 mg 
Prednisone 
10mg 
Azathioprine 
100 mg 
Cyclosporine 
240 mg 
Prednisone 
10mg 
Cyclosporine 
240 mg 
Prednisone 
10mg 
Cyclosporine 
240 mg 
Prednisone 
10mg 
Cyclosporine 
240 mg 
Prednisone 
10mg 
Cyclosporine 
240 mg 
Prednisone 
10mg 
Yes, mild No No 
to moderate 
No No No 
Yes, mild No Cotrimoxazole 
to moderate course for 
PCP 
No AZT 500 mg Aerosolized 
pentamidine 
No ATT 500 mg Aerosolized 
pentamidine 
No AZT 500 mg Aerosolized 
pentamidine 
No AZT 500 mg Aerosolized 
pentamidine 
No AZT 500 mg, Cotrimoxazole 
then course for 
DDI 400 mg PCP 
*Quantitative determination by acidified p24 antigen assay; PCP = Pneumocystis carhi; CMV = cytomegalovirus; ND = not determined. 
negative for E! curinii and acid-fast bacilli; immunofluo- 
rescence for ~65 antigen of cytomegalovirus (CMV) in 
peripheral blood granulocytes was negative. Myocardial 
biopsy did not show any sign of myocardial infiltrate- 
HIV myocarditis and acute chronic rejection were sus- 
pected. Zidovudine was discontinued and dopamine, 
ceftriaxone, cotrimoxazole, didanosine, and intravenous 
methylprednisolone boluses were administered.Two days 
later, the patient died suddenly. 
Autopsy examination yielded PCP and CMV pneu- 
monia with mild interstitial fibrosis; there was evidence 
of a dilated heart; there were no signs of myocarditis or 
either acute or chronic rejection. 
DISCUSSION 
Table 2 presents all cases of HIV infection following heart 
transplantation that have appeared in the scientific liter- 
ature; all of the cases were males between 20 and 55 
years of age.This case (patient number 7) presents some 
interesting characteristics when compared to previous 
reports. No case of HIV infection has been reported in 
transplanted patients since 1987.Although it is possible 
that other transfusion-related infections have occurred, 
certainly routine testing of blood and organ donors for 
antibodies to HIV and current virus inactivation proce- 
dures used in the production of coagulation factors have 
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Table 2. Epidemiologic and Clinical Characteristics of Patients 
with HIV Infection Acquired after Heart Transplantation 
Last Negative/ Time to 
Date of First Positive AIDS (mo post Graft 
Pa tien tRef Transplant HIV Antibodies transplant) Function 
, 1.2 1982 43d/49d 13 Normal 
212 1982 75dJl89d NR Normal 
3’ e i 983 2adh4d NR Rejection 
41.2 1984 24d/46d NR Rejection 
53 1984 NR/SOOd NR Normal 
64 i 984 NR/740d NR Normal 
75 1985 NR/240d 6 Normal 
NR = not reported. 
largely reduced the risk of HIV transmission to recipients 
of transplanted organs. 
Unfortunately, a “window” of 6 to 8 weeks exists 
between HIV infection and antibody response as detected 
by the usual laboratory methods.6x7 This was the case in 
the patient presented here, who was transfused with 
blood harvested from a donor during the window period. 
Therefore, a low risk of acquiring HIV infection by trans- 
fusion still exists. 
It has been debated whether the course of HIV infec- 
tion is more severe in transplanted patients, who are phar- 
macologically immunosuppressed. Although the 
proportion of patients who develop AIDS is not higher 
than in other groups of HIV-infected individuals, it has 
been reported that HIV-infected recipients of transplanted 
organs may develop AIDS sooner4 As shown in Table 2 
and excluding patients 3 and 4, who died of rejection 
shortly after transplantation, two of five (40%) HIV- 
infected heart transplant recipients developed AIDS with 
a mean time of progression toAIDS of 9.5 + 2.9 months. 
From this evidence it seems that heart transplanted 
patients have a poorer prognosis than other transplanted 
patients, whose mean time of progression to AIDS is 32 
months.* However, it should be noted that AIDS was 
defined by the Centers for Disease Control and Preven- 
tion (CDC) as the presence of pathologic conditions indi- 
cating reduced cellular immunity in the absence of any 
other cause of immunosuppression8; transplanted patients 
are pharmacologically immunosuppressed, so they do not 
properly fit CDC criteria for the AIDS definition. Thus, 
evaluations based on the time of progression from a pos- 
itive serology to an AIDS-defining illness may not be ade- 
quate for judging prognosis. 
Other issues are the rate and the severity of rejection 
in HIV infected patients: it has been observed that some 
HIV-positive kidney and liver recipients maintained nor- 
mal allograft function despite substantial reduction or 
total discontinuation of immunosuppressive therapy4 This 
is controversial in heart transplanted patients, since two 
of eight patients died of acute rejection and two other 
patients showed severe rejection episodes. In contrast, 
the patient in the present study had few mild-to-moder- 
ate rejection episodes during the first postoperative years 
and was subsequently free from acute rejection, although 
azathioprine was discontinued. Furthermore no sign of 
rejection or coronary artery disease was found at autopsy 
It is possible that the necessity for immunosuppressive 
therapy decreases during progression of HIV disease, but 
it seems unwise to markedly reduce immunosuppressive 
therapy in HIV-positive heart transplanted patients, since 
the risk of damaging heart function is lethal. 
The patient in this study died due to heart failure. He 
had a progressive decline in heart function during the 
last year and dilated cardiomyopathy was found and con- 
firmed at autopsy. The etiology of cardiomyopathy 
remains unknown. One hypothesis is that heart failure 
was related to zidovudine treatmentThe patient had been 
administered zidovudine for 4 consecutive years, and the 
drug was discontinued only a few days before death. Dif- 
fuse cardiac mitochondrial ultrastructural defects have 
been seen in rats receiving long-term zidovudine treat- 
ment,9 and an association has been reported between 
zidovudine treatment and the development of car- 
diomyopathy in patients with HIV infection.” However, 
larger studies have not shown a significant association 
between myocardial disfunction and zidovudine treat- 
ment in HIV-positive patients. l1 An alternative hypothe- 
sis is that heart failure was due to HIV-induced 
cardiomyopathy. Myocardial involvement has been 
reported during HIV infection,1’s13 and HIV itself can 
cause myocarditis and dilated cardiomyopathy.14J5 How- 
ever, no histologic evidence of myocarditis was observed 
at repeated myocardial biopsies and autopsy in this 
patient. 
The patient survived longer than expected, based on 
his CD4+ lymphocyte count. He survived 84 months with 
a CD4+ lymphocyte level lower than 200/mm3, whereas 
patients with this degree of immunosuppression have 
been reported to survive 15.7 to 41.0 months.13J6 Fur- 
thermore, this patient survived 52 months after AIDS diag- 
nosis, versus 19.8 to 25.6 months for comparable 
patients. 17,18 These fmdings suggest the intriguing issue of 
a possible benefit from cyclosporine administration in 
addition to zidovudine treatment in this patient. 
Cyclosporine has been reported to reduce HIV-l 
infectivity by binding to the cellular protein cyclophilin 
A 19,20 whose interaction with the principal structural pro- 
tein of HIV the Gag polyprotein, is necessary for retroviral 
virion assembly.*l Since cyclosporine and zidovudine act 
on different steps of HIV replication, the two drugs may 
have a synergistic effect. Unfortunately, inadequate data 
are available to correlate cyclosporine treatment, with or 
without AZT, on levels of immunosuppression and sur- 
vival.The two drugs failed to significantly decrease serum 
HIV p24 antigen levels in the patient presented here. 
Since HIV replication seems to be inhibited in vitro by 
cyclosporine concentrations that are lo- to lOO-fold 
higher than are necessary for immunosuppression in 
vivo,21 a correlation between cyclosporine-zidovudine 
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administration and long-term survival in this patient 
remains doubtful. 
In conclusion, although it has been reported that the 
outcome of HIV infection seems to be worse in heart 
recipients in comparison with other transplanted patients, 
heart transplantation can significantly improve survival in 
patients with severe cardiopathy. It has been postulated 
that HIV infection should not be an absolute contraindi- 
cation to transplantation.a2 Considering the expense of 
heart transplantation and the limited number of available 
organs the authors do not support this opinion, but expe- 
rience suggests that survival in patients treated with 
cyclosporine may be better than previously reported. 
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